Literature DB >> 22969091

Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation.

Tomofumi Fujino1, Airi Takeuchi, Akiko Maruko-Ohtake, Yosuke Ohtake, Junichi Satoh, Tomonori Kobayashi, Toshiaki Tanaka, Haruka Ito, Ryosuke Sakamaki, Ryo Kashimura, Ken Ando, Tomoko Nishimaki-Mogami, Yasuhito Ohkubo, Naomi Kitamura, Ryuichiro Sato, Kiyomi Kikugawa, Makio Hayakawa.   

Abstract

Farnesoid X receptor (FXR), a pivotal factor maintaining bile acid homeostasis, has been recently shown to be a critical factor required for liver regeneration. The elucidation of the mechanism how FXR controls the proliferation of hepatocellular carcinoma cells is useful to establish the therapy for liver cancer. Here, we show that FXR plays a crucial role in the proliferation of human hepatocellular carcinoma cell line, HepG2, Huh7 and HLE. The treatment of HepG2 with FXR siRNA elevates the level of p16/INK4a expression resulting in the inhibition of cell proliferation. By contrast, FXR activation reduces p16/INK4a expression and stimulates the cell proliferation. The ectopic expression of the active form of Ras that causes strong activation of extracellular signal-regulated kinase (ERK) leads to the decrease in FXR expression, suggesting that FXR expression is negatively regulated via Ras/ERK pathway. The elevation of p16/INK4a expression and the inhibition of cell proliferation by FXR knockdown are also observed in Huh7 and HLE. In this study, we have suggested a novel mechanism by which hepatocellular carcinoma cell proliferation is regulated: FXR stimulates cell proliferation by suppressing the p16/INK4a expression, whereas Ras/ERK pathway down-regulates the FXR expression, leading to the suppressed cell proliferation in hepatocellular carcinoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22969091     DOI: 10.1093/jb/mvs101

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  11 in total

1.  Revealing the macromolecular targets of complex natural products.

Authors:  Daniel Reker; Anna M Perna; Tiago Rodrigues; Petra Schneider; Michael Reutlinger; Bettina Mönch; Andreas Koeberle; Christina Lamers; Matthias Gabler; Heinrich Steinmetz; Rolf Müller; Manfred Schubert-Zsilavecz; Oliver Werz; Gisbert Schneider
Journal:  Nat Chem       Date:  2014-11-02       Impact factor: 24.427

Review 2.  Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.

Authors:  Jessica Tsuei; Thinh Chau; David Mills; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

3.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

4.  AU-1 from Agavaceae plants causes transient increase in p21/Cip1 expression in renal adenocarcinoma ACHN cells in an miR-34-dependent manner.

Authors:  Tomofumi Fujino; Akihito Yokosuka; Hideaki Higurashi; Rina Yokokawa; Ryo Sakurai; Wataru Harashima; Yuichi Miki; Yasuyuki Fujiwara; Yoshihiro Mimaki; Makio Hayakawa
Journal:  J Nat Med       Date:  2016-07-07       Impact factor: 2.343

5.  Simultaneous bile duct and portal vein ligation induces faster atrophy/hypertrophy complex than portal vein ligation: role of bile acids.

Authors:  Weizheng Ren; Geng Chen; Xiaofeng Wang; Aiqun Zhang; Chonghui Li; Wenping Lv; Ke Pan; Jia-Hong Dong
Journal:  Sci Rep       Date:  2015-02-13       Impact factor: 4.379

6.  FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach.

Authors:  Weiqiang Lu; Feixiong Cheng; Jing Jiang; Chen Zhang; Xiaokang Deng; Zhongyu Xu; Shien Zou; Xu Shen; Yun Tang; Jin Huang
Journal:  Sci Rep       Date:  2015-01-29       Impact factor: 4.379

7.  Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway.

Authors:  Sumet Amonyingcharoen; Tawit Suriyo; Apinya Thiantanawat; Piyajit Watcharasit; Jutamaad Satayavivad
Journal:  Int J Oncol       Date:  2015-03-27       Impact factor: 5.650

8.  Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming.

Authors:  Yang Xie; Hong Wang; Xuefang Cheng; Yuzheng Wu; Lijuan Cao; Mengqiu Wu; Wen Xie; Guangji Wang; Haiping Hao
Journal:  Sci Rep       Date:  2016-01-05       Impact factor: 4.379

Review 9.  Disease monitoring of hepatocellular carcinoma through metabolomics.

Authors:  Asem I Fitian; Roniel Cabrera
Journal:  World J Hepatol       Date:  2017-01-08

Review 10.  Molecular Targets in Hepatocarcinogenesis and Implications for Therapy.

Authors:  Meng-Yu Wu; Giuo-Teng Yiang; Pei-Wen Cheng; Pei-Yi Chu; Chia-Jung Li
Journal:  J Clin Med       Date:  2018-08-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.